Oxford Gene Technology (OGT) is to develop a tumour profiling assay based on targeted panel enrichment and next-generation sequencing (NGS).
The new assay will be designed to improve cancer care by providing specific information about each individual sufferer, facilitating the design of personalised treatment strategies.
This will hopefully minimise the use of untargeted, aggressive primary treatments, which are often unnecessary and ineffective, while simultaneously improving the patient experience and increasing survival rates.
The assay will detect mutations at informative loci, forming part of an integrated workflow that translates test results into clear clinical decisions.
Such a solution could be provided as either a testing service or by the sale of an analysis 'kit' that could be used in house by existing clinical laboratories.
In addition, OGT will adapt its Cytosure Interpret software to analyse the results provided by the new assays, making it simple to generate informative reports.
